

PDCD1 & CTLA4 Research Grade Vudalimab

Catalog No.	DHH02222A DHH02222B	Quantity:	100 µg 1.0 mg
Alternate Names:	Bispecific, XmAb-20717, XMAB20717, CAS: 2329669-72-7		
Description:	Research Grade Vudalimab is a bispecific humanized monoclonal antibody directed against human Programmed cell death protein 1 (PD-1, CD279) and Cytotoxic T-lymphocyte protein 4 (CD152)		
UniProt ID (target):	Q15116 & P16410		
Target:	Bispecific human Programmed cell death protein 1 (PD-1, CD279) and Cytotoxic T-lymphocyte protein 4 (CD152)		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3		
Formulation:	Sterile-filtered 0.01 M PBS, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Vudalimab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.